NasdaqGS:JAZZPharmaceuticals
A Look At Jazz Pharmaceuticals (JAZZ) Valuation After Ziihera Priority Review Milestone
Jazz Pharmaceuticals (JAZZ) is back in focus after US regulators accepted a priority review of its supplemental biologics application for Ziihera in HER2-positive advanced gastroesophageal cancers, supported by pivotal Phase 3 HERIZON-GEA-01 data.
See our latest analysis for Jazz Pharmaceuticals.
Alongside the FDA priority review and a busy oncology conference schedule, Jazz Pharmaceuticals’ 1 month share price return of 7.68% and 90 day share price return of 23.24% feed into a 1 year total...